These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17317184)

  • 1. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series.
    Hagen AI; Kvistad KA; Maehle L; Holmen MM; Aase H; Styr B; Vabø A; Apold J; Skaane P; Møller P
    Breast; 2007 Aug; 16(4):367-74. PubMed ID: 17317184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk.
    Podo F; Sardanelli F; Canese R; D'Agnolo G; Natali PG; Crecco M; Grandinetti ML; Musumeci R; Trecate G; Bergonzi S; De Simone T; Costa C; Pasini B; Manuokian S; Spatti GB; Vergnaghi D; Morassut S; Boiocchi M; Dolcetti R; Viel A; De Giacomi C; Veronesi A; Coran F; Silingardi V; Turchett D; Cortesi L; De Santis M; Federico M; Romagnoli R; Ferrari S; Bevilacqua G; Bartolozzi C; Caligo MA; Cilotti A; Marini C; Cirillo S; Marra V; Martincich L; Contegiacomo A; Pensabene M; Capuano I; Burgazzi GB; Petrillo A; Bonomo L; Carriero A; Mariani-Costantini R; Battista P; Cama A; Palca G; Di Maggio C; D'Andrea E; Bazzocchi M; Francescutti GE; Zuiani C; Londero V; Zunnui I; Gustavino C; Centurioni MG; Iozzelli A; Panizza P; Del Maschio A
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):115-24. PubMed ID: 12585665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer.
    Riedl CC; Ponhold L; Flöry D; Weber M; Kroiss R; Wagner T; Fuchsjäger M; Helbich TH
    Clin Cancer Res; 2007 Oct; 13(20):6144-52. PubMed ID: 17947480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study.
    Warner E; Causer PA; Wong JW; Wright FC; Jong RA; Hill KA; Messner SJ; Yaffe MJ; Narod SA; Plewes DB
    Breast J; 2011; 17(1):9-17. PubMed ID: 21251121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
    Obdeijn IM; Winter-Warnars GA; Mann RM; Hooning MJ; Hunink MG; Tilanus-Linthorst MM
    Breast Cancer Res Treat; 2014 Apr; 144(3):577-82. PubMed ID: 24567197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stage of breast cancers found during the surveillance of women with a familial or hereditary risk.
    Kaas R; Muller SH; Hart AA; Rutgers EJ
    Eur J Surg Oncol; 2008 May; 34(5):501-7. PubMed ID: 17555911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study.
    Rijnsburger AJ; Obdeijn IM; Kaas R; Tilanus-Linthorst MM; Boetes C; Loo CE; Wasser MN; Bergers E; Kok T; Muller SH; Peterse H; Tollenaar RA; Hoogerbrugge N; Meijer S; Bartels CC; Seynaeve C; Hooning MJ; Kriege M; Schmitz PI; Oosterwijk JC; de Koning HJ; Rutgers EJ; Klijn JG
    J Clin Oncol; 2010 Dec; 28(36):5265-73. PubMed ID: 21079137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
    Warner E; Plewes DB; Hill KA; Causer PA; Zubovits JT; Jong RA; Cutrara MR; DeBoer G; Yaffe MJ; Messner SJ; Meschino WS; Piron CA; Narod SA
    JAMA; 2004 Sep; 292(11):1317-25. PubMed ID: 15367553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for hereditary breast cancer.
    Dent R; Warner E
    Semin Oncol; 2007 Oct; 34(5):392-400. PubMed ID: 17920893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI screening in a clinic population with a family history of breast cancer.
    Yu J; Park A; Morris E; Liberman L; Borgen PI; King TA
    Ann Surg Oncol; 2008 Feb; 15(2):452-61. PubMed ID: 18026801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
    Møller P; Stormorken A; Jonsrud C; Holmen MM; Hagen AI; Clark N; Vabø A; Sun P; Narod SA; Mæhle L
    Breast Cancer Res Treat; 2013 May; 139(1):155-61. PubMed ID: 23615785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS).
    Leach MO; Eeles RA; Turnbull LW; Dixon AK; Brown J; Hoff RJ; Coulthard A; Dixon JM; Easton DF; Evans DG; Gilbert FJ; Hawnaur J; Hayes C; Kessar P; Lakhani S; Liney G; Moss SM; Padhani AP; Pointon LJ; Sydenham M; Walker LG; Warren RM; Haites NE; Morrison P; Cole T; Rayter Z; Donaldson A; Shere M; Rankin J; Goudie D; Steel CM; Davidson R; Chu C; Ellis I; Mackay J; Hodgson SV; Homfray T; Douglas F; Quarrell OW; Eccles DM; Gilbert FG; Crothers G; Walker CP; Jones A; Slack N; Britton P; Sheppard DG; Walsh J; Whitehouse G; Teh W; Rankin S; Boggis C; Potterton J; McLean L; Gordon PA; Rubin C;
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):107-14. PubMed ID: 12585664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of interval breast malignancies in patients with BRCA mutations.
    Komenaka IK; Ditkoff BA; Joseph KA; Russo D; Gorroochurn P; Ward M; Horowitz E; El-Tamer MB; Schnabel FR
    Cancer; 2004 May; 100(10):2079-83. PubMed ID: 15139048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
    Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
    Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary breast cancer growth rates and its impact on screening policy.
    Tilanus-Linthorst MM; Kriege M; Boetes C; Hop WC; Obdeijn IM; Oosterwijk JC; Peterse HL; Zonderland HM; Meijer S; Eggermont AM; de Koning HJ; Klijn JG; Brekelmans CT
    Eur J Cancer; 2005 Jul; 41(11):1610-7. PubMed ID: 15978801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-risk screening: multi-modality surveillance of women at high risk for breast cancer (proven or suspected carriers of a breast cancer susceptibility gene).
    Kuhl CK
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):103-6. PubMed ID: 12585663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
    Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI in breast cancer management: potential for benefit and harm.
    Jatoi I
    Int J Fertil Womens Med; 2005; 50(6):281-4. PubMed ID: 16526420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on screening breast MRI in high-risk women.
    Boetes C
    Magn Reson Imaging Clin N Am; 2010 May; 18(2):241-7, viii. PubMed ID: 20494309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.